Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits

被引:17
作者
Ernofsson, M
Thelin, S
Siegbahn, A
机构
[1] UNIV UPPSALA HOSP,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA HOSP,DEPT CARDIOVASC THORAC SURG,S-75185 UPPSALA,SWEDEN
来源
SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY | 1995年 / 29卷 / 04期
关键词
cardiopulmonary bypass; heparin coating; biocompatible surfaces; thrombin generation; thrombin-antithrombin III complex; prothrombin fragment 1+2;
D O I
10.3109/14017439509107224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
For quantitative comparison of thrombin generation during cardiopulmonary bypass (CPB) with heparin-coated vs conventional CPB circuits, thrombin-antithrombin III complex (TAT) and prothrombin fragment 1+2 (F-1+2) were analyzed in 20 patients undergoing combined heart valve surgery and coronary artery bypass grafting (CABG), in ten cases with heparin-coated circuits (COMB-HC) and in ten with standard circuits (COMB-C). Extensive thrombin generation was found in both groups, with maximal TAT and F-1+2 levels at the end of CPB. Of 15 operations with only CABG, seven were performed with heparin-coated circuits and heparin dose 40% of normal (CABG-HC), and eight with standard circuits and normal heparin doses (CABG-C). TAT was maximal at the end of CPB and F-1+2 peaked 3 hours after protamine injection. At the end of CPB both levels were significantly higher in the CABG-HC than in the CABG-C group, though thrombin generation was less than in the COMB groups. The abundant thrombin generation during CPB thus was much more pronounced during complex operations. Use of heparin-coated circuits did not reduce thrombin generation, which was increased by 60% reduction of the systemic heparin dose. The clinical implications are still unknown, as no complications were observed.
引用
收藏
页码:157 / 165
页数:9
相关论文
共 37 条
  • [1] BINDING OF THROMBIN TO SUBENDOTHELIAL EXTRACELLULAR-MATRIX - PROTECTION AND EXPRESSION OF FUNCTIONAL-PROPERTIES
    BARSHAVIT, R
    ELDOR, A
    VLODAVSKY, I
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) : 1096 - 1104
  • [2] BOISCLAIR MD, 1993, BLOOD, V82, P3350
  • [3] BOISCLAIR MD, 1993, THROMB HAEMOSTASIS, V70, P253
  • [4] DECREASED BLOOD-LOSS AFTER CARDIOPULMONARY BYPASS USING HEPARIN-COATED CIRCUIT AND 50-PERCENT REDUCTION OF HEPARIN DOSE
    BOROWIEC, J
    THELIN, S
    BAGGE, L
    HULTMAN, J
    HANSSON, HE
    [J]. SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1992, 26 (03): : 177 - 185
  • [5] BOROWIEC J, 1992, J THORAC CARDIOV SUR, V104, P642
  • [6] HEPARIN-COATED CARDIOPULMONARY BYPASS CIRCUITS AND 25-PERCENT REDUCTION OF HEPARIN DOSE IN CORONARY-ARTERY SURGERY - A CLINICAL-STUDY
    BOROWIEC, J
    THELIN, S
    BAGGE, L
    VANDERLINDEN, J
    THORNO, E
    HANSSON, HE
    [J]. UPSALA JOURNAL OF MEDICAL SCIENCES, 1992, 97 (01) : 55 - 66
  • [7] BRISTER SJ, 1993, THROMB HAEMOSTASIS, V70, P259
  • [8] COMPLEMENT ACTIVATION DURING CARDIOPULMONARY BYPASS - EVIDENCE FOR GENERATION OF C3A AND C5A ANAPHYLATOXINS
    CHENOWETH, DE
    COOPER, SW
    HUGLI, TE
    STEWART, RW
    BLACKSTONE, EH
    KIRKLIN, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (09) : 497 - 503
  • [9] Conover WJ, 1980, PRACTICAL NONPARAMET, P299
  • [10] ELGUE G, 1993, THROMB HAEMOSTASIS, V70, P289